Mizuho Maintains Buy on Revance Therapeutics, Lowers Price Target to $16
Portfolio Pulse from Benzinga Newsdesk
Mizuho analyst Uy Ear has maintained a Buy rating on Revance Therapeutics (NASDAQ:RVNC) but has reduced the price target from $35 to $16.
November 22, 2023 | 4:49 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Revance Therapeutics' price target has been lowered from $35 to $16 by Mizuho, although the Buy rating is maintained.
The reduction in price target by more than 50% indicates a significant change in the expected future performance of the company, which could lead to a negative short-term impact on the stock price. However, the maintenance of a Buy rating suggests underlying confidence in the company's long-term prospects.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100